

# Annual Report 2018



# **Our Mission**

The Cancer Society aims to reduce the incidence and impact of cancer and our objectives include:

- Supporting and funding research within New Zealand into the prevention, treatment and cure of cancer.
- Providing supportive care and information to people affected by cancer, their families/ whānau and carers.
- Promoting education about cancer for health professionals and publicising progress made in research and treatment.
- Delivering health promotion programmes focusing on cancer prevention.
- Leading advocacy across the cancer continuum.
- Working collaboratively with organisations who share similar goals to the Cancer Society.

# The incidence of cancer in New Zealand is increasing

# CANCER IS NOW THE LEADING CAUSE OF DEATH IN NEW ZEALAND

THERE ARE OVER

23000

PEOPLE DIAGNOSED YEARLY

MORE THAN THE POPULATION OF



THERE HAS BEEN ALMOST A 30 PERCENT INCREASE

# OVER THE PAST 10 YEARS

3474 registrations 1983 **10330** registrations 2015 23215 registrations


BY THE YEAR

THERE WILL BE 50% INCREASE OF 50%

9500

NEW ZEALANDERS DIE FROM CANCER EACH YEAR

**CANCER ACCOUNTS FOR** 





- According to the latest figures, 30.2% of all deaths in New Zealand are from cancer
- This figure is expected to increase by around 61% in 2035
- We have the highest rate of melanoma in the world
- And one of the highest rates of bowel cancer
- The cancer mortality rate for Māori is 1.5 times the rate for non-Māori
- Along with Australia, we have the highest rates of prostate cancer in the world
- Each year 3272 women are diagnosed with breast cancer.

4 Cancer Society Annual Report 2018 Cancer Society Annual Report 2018 5

# President's report - Peter Hutchison



The Cancer Society is in good shape. National Office work closely with our six autonomous Divisions to reduce the impact and incidence of cancer.

### Governance review completed:

Over the last few years we conducted a full review of the governance of the National Office and refined our operational focus to the core areas of the cancer continuum.

The Cancer Society is committed to staying at the forefront of these areas to help meet the needs of people with cancer. Over the coming year we will be thinking carefully about where we are going, what our core services should be, and where our focus best sits so that we are fit-for-purpose in this high-demand environment.

### Advocacy is a vital part of what we do:

With cancer now being the biggest killer of New Zealanders, advocacy is a vital part of what we do. We are very aware of the inequities existing in health statistics. This will be a key focus in how we advocate for improvements.

### Thank you to our supporters:

Our organisation remains fundamentally sound. I'd like to thank all our many supporters, volunteers, donors, corporate partners, and especially our major sponsor ANZ, for your continued support of the Cancer Society. Without our big events like Daffodil Day we would not be able to continue our work supporting people with cancer in our communities.

I want to thank all staff for your hard work and commitment and acknowledge the contribution that the staff and Board of Daffodil Enterprises Ltd make to the Cancer Society. I am very appreciative of the commitment made by my fellow Board members, thank you to this year's exiting member, Stuart Bauld, for your commitment to our work. Last, but not least, a big thank you to our Medical Director, Dr Chris Jackson, who works tirelessly advocating on behalf of people with cancer.

Chief Executive Mike Kernaghan on the left, with Peter Hutchison, President of the Cancer Society of New Zealand.

# Chief Executive's report - Mike Kernaghan



Cancer Society volunteer drivers receiving their runner-up award from the Minister of Health's Volunteer Awards November 2017.



ANZ and their staff are key to the success of Daffodil Day.

Here at the Cancer Society of New Zealand our role as advocates for people affected by cancer is an important one.

### Highlighting cancer-care concerns:

This year we welcomed the opportunity to work with the new government to better highlight cancer-care concerns. This included a briefing to the new Minister of Health, working with the Ministry of Social Development on the medical certificate requirements of cancer patients and the Ministry of Health on the National Travel Assistance Scheme.

We continue to work alongside the Central Cancer Network and the Cancer Nurses College to develop a survivorship consensus statement. Working across the cancer continuum, promoting key health messages in areas such as SunSmart and Smokefree New Zealand remains a priority for how we address the incidence of cancer.

### Research is an important part of what we do:

This year we were pleased to develop a new research strategy for the next five years with six new research goals that you can read about in the research section of this report.

### High awareness of the Cancer Society brand:

Our recent brand evaluation showed that there is a high awareness of the Cancer Society and that we have a positive profile in the media. Our Medical Director Dr Chris Jackson's eloquent and decisive advocacy has played a big part in this.

### Volunteers at the centre of everything we do:

This year we developed a new volunteer strategy to entrench our commitment to the thousands of volunteers who make our work possible. I'd like to congratulate our volunteer drivers who were runners-up in the Minister of Health's volunteer awards recognition of the important work they do.

### Our team at National Office:

We have a skilled and engaged team here in our National Office, all of whom are passionate about making a difference for people affected by cancer. Working collaboratively across teams and geographic boundaries, we all have the opportunity to work on matters of national importance. I'd like to acknowledge the staff for all their hard work - we have a great team.

I would like to thank the National Board, members of the National Scientific Advisory Committee, National Health Promotion Advisory Committee, and our National Finance Audit and Risk Committee for your ongoing support and commitment to the Cancer Society. A sincere thank you to the ANZ and your staff for your ongoing support, this contributes greatly to the work we do.

# The Cancer Society in New Zealand


# The national picture

The Cancer Society is a federation consisting of a National Office and six Divisions with 24 offices. The Divisions deliver care and support to people affected by cancer in their communities.

Each Division is represented on the National Board that governs the Cancer Society of New Zealand and its operative arm, the National Office. The National Office has a key advocacy and national co-ordination role working closely with our Divisions to support what they do.

This map shows where we are located over the country.





# Cancer research funding

The National Office of the Cancer Society funded \$1.425 million in research in the 2017-18 year to help advance cancer-related knowledge. The Cancer Society of New Zealand funds research through the Cancer Society Social and Behavioural Research Unit at the University of Otago (CSSBRU) - \$392,500 and the Research Grants Programme - \$1,032,184. No training scholarships were funded this year.

### The Cancer Society Social and Behavioural Research Unit - \$392,500

Key areas of focus over the past year include:

- tobacco control
- sun protection and ultraviolet radiation-related studies
- cancer awareness and information provision
- supportive care and survivorship.

### Cancer risk awareness increases

One study carried out by the CSSBRU this year, explored aspects of cancer awareness, including awareness of risk factors for different types of cancer. The study showed that since 2001, there have been significant increases in awareness that adequate sun protection, avoiding sunbeds/solaria, healthy weight, limiting red meat and alcohol, and diets high in fruit and vegetables decrease the risk of developing cancer.

### Read about the work of the CSSBRU at www.otago.ac.nz/sbru



### Research Grants Programme - \$1,032,184

This year our Research Grants Programme funded five projects:

### 1. David Barker from University of Auckland (awarded \$304,940)

A group of University of Auckland researchers are developing new drugs that may provide better treatment options for people with metastatic breast cancer.

### 2. Michael Hay from University of Auckland (awarded \$147,334)

Researchers at the University of Auckland will explore how cancer cells repair themselves after being treated with chemotherapy or radiotherapy. This research study will investigate ways to prevent cancer cells from using repair mechanisms to escape the full effects of chemotherapy and radiotherapy.

### 3. Merilyn Hibma from University of Otago, Dunedin (awarded \$299,159)

Researchers aim to identify new immune system targets to further improve treatment of cancer.

### 4. Winston McEwan from Waikato District Health Board (awarded - \$197,448)

Researchers at Waikato District Health Board have been funded to carry out a clinical trial that explores new uses for a type of surgery to improve lymphoedema (tissue swelling). Lymphoedema is a common and lingering side effect of surgical cancer treatment that reduces survivor's quality of life.

### 5. Sarah Hook from University of Otago, Dunedin (awarded \$83,302)

Researchers from the Otago University School of Pharmacy, will test a new oral immunotherapy treatment for colorectal cancer that may be less toxic than existing treatments.

### New research strategy 2018-2023

With an expert advisory group making recommendations on the future direction of our research programme, our new strategy outlines how we will achieve our research goals over the next five years. The research strategy goals are:

- high-quality and high-impact research funded through an open and transparent funding process
- funded research projects focus on the priorities of the Cancer Society
- additional funding is leveraged into cancer research in New Zealand
- increase national awareness of the Cancer Society's research programme
- Cancer Society funded research improves equitable cancer outcomes across the cancer continuum for all New Zealanders
- commitment to the Treaty of Waitangi is evident throughout the research funding process.

Learn more about the cancer research we support at www.cancernz.org.nz

12 Cancer Society Annual Report 2018 Cancer Society Annual Report 2018

# Why do some countries have better cancer survival rates than others and what can we learn from this?

The Cancer Society continues to invest in the International Cancer Benchmarking Project, led by the Cancer Research UK.

This collaboration seeks to not only identify international differences in cancer survival, but also to explore what might influence those differences. This includes topics such as treatment, screening, access to diagnostics, cancer patient pathways and health system factors such as health care funding and expenditure.



### Information resources

Providing easy-to-understand information on cancer treatment and support is a core part of what we do. Last year there were a total of 44,753 individual copies of publications and resources distributed through the Cancer Society to people affected by cancer and to the general public as health promotion messages.


### Cancer survivorship

As treatments improve and more people are living longer with cancer, the Cancer Society is increasingly focused on survivor's ongoing needs. This year the Cancer Society worked with the Central Cancer Network and the Cancer Nurses College to complete the Cancer Survivorship in New Zealand consensus statement. The consensus statement outlines the importance of survivorship, includes a focus on improving equity, and highlights what high-quality survivorship looks like. In the coming year the Cancer Society will be working with the Ministry of Health to continue progressing this important work.



# Our work in health promotion

We continue to deliver key health promotion activities in the areas of: Smokefree, SunSmart, screening and early detection, obesity and alcohol related cancer. We work to address the inequity of cancer outcomes for high priority groups to reduce the incidence and impact of cancer.



14 Cancer Society Annual Report 2018 Cancer Society Annual Report 2018 15

# SunSmart schools and early childhood centres

In October 2017, an online professional development module on becoming SunSmart for early childhood teachers was set-up, trialled, and launched. As a tool to increase the uptake of SunSmart messages in an easy-to-use format, it has been quickly taken up by early childhood teachers and parents. The educators get a certificate to add to their professional development folder, an added incentive.

### **Number of registrations**








9 March 2018 418

### Accredited SunSmart schools 41.26%

The number of schools who are actively SunSmart has reached 41.26% of all primary and intermediate schools.

These schools are accredited with policies and processes to ensure sun protection in their schools and their activities.





16 | Cancer Society Annual Report 2018 Cancer Society Annual Report 2018 | 17

# Our supporters

As an independent charity without direct government funding, our fundraising activities are important. We could not provide the level of service we provide without our supporters. Key fundraising events such as our annual Daffodil Day appeal and Relay For Life call on the support of many volunteers, staff and donors to generate funds in communities throughout New Zealand. We acknowledge the support we also receive from bequests and payroll giving.

### **Daffodil Day**

Since 1990 Daffodil Day has inspired people to come together and support our work, as well as providing an opportunity to raise awareness of cancer in New Zealand. Daffodil Day figures for 31 August 2017:

- \$4.5 million raised
- 11,900 volunteers on the streets
- 1.058 collection sites
- Thousands of local businesses collecting donations
- 28 years of support from our principal sponsor ANZ

A key contributor to Daffodil Days success is our principal sponsor ANZ. This year ANZ raised \$790,753 through local branch collections and fundraising by their passionate staff.





### **Principal Sponsor**

Thanks to our other national supporters: Eftpos New Zealand Signature Promotions Fuji Xerox

### **Bequests**

Bequests are a vital source of support for us and our active bequest programme is an opportunity to honour supporters during their lifetime while supporting the work we do. Bequests go directly to Cancer Society Divisions to support our advocacy, information and research.



### Payroll giving

As an approved Inland Revenue donee organisation the Cancer Society has been nominated by a number of organisations to receive donations through payroll giving. Thank you to the following organisations and the employees of:

Chartered Accountants of Australia and New Zealand Department of Internal **Affairs Event Hotels** Inland Revenue Ipayroll Ministry of Education Ministry of Social Development

Rabobank Rialto Cinemas Rydges Latimer Hotel Rydges Rotorua Hotel Spark The Warehouse Group Wellington Hotel Investments Limited

New Bay Investment



### Relay For Life - it's all about community

Relay For Life is an inspiring community event that gives everyone a chance to celebrate cancer survivors and carers, remember loved ones, and fight back by raising awareness and funds to support the work of the Cancer Society. It is for people of all ages and fitness levels and is an annual event held across the country. Relay For Life is a key way that we engage with our communities.

To provide the best experience for our volunteers and Relay For Lifers, this year staff took part in an international training event with the aim to build on our community engagement skills, while connecting with our Relay For Life global partners. Key achievements last year:

- 17 relays across the country
- 862 teams with 14,429 team members
- 2,644 survivors and carers
- over \$2 million was raised

www.relayforlife.org.nz

# Our people

# A national picture of our workforce



National Office staff August 2018

### **National Office staff**

Annita Patel
Ashten Macdonald
Dani McIntosh
Daniel Glover
Hazem Abd Elkader
Heather Knewstubb
Helga Wientjes
Hypatia Stacy-Baynes

Inga O'Brien
Jack Milton
Janine Neal
Kate Hindle
Leigh Taggart
Louise Sandford
Mary Ryan
Melanie Metuariki

Mike Kernaghan Rachel Nicholls Sarah Campbell Shayne Nahu Vicki Ambrose Vicky Shuker

### **National Office volunteers**

Bryony Aitken-Fincham Rachael Nunn Valerie Nahu

### **Daffodil Enterprises Ltd**

Fiona Mawley Karen Ilton

### **National Board**

Peter Hutchison
Stuart Bauld
Dr Chris Jackson
Kate Morrison
Murray Loewenthal
Garry Forgeson
Jonathan Koea
Neil Boniface
Elizabeth Chesterman
Alister Argyle

President NFARAC Chair Medical Director Wellington Division Waikato/Bay of Ple

Waikato/Bay of Plenty Division Central Districts Division Auckland/Northland Division Otago/Southland Division

**NEC Representative** 

Canterbury/West Coast Division



### Volunteer drivers runners-up in Minister of Health volunteer awards

For fifty years, our volunteer drivers throughout the country have made sure cancer patients with limited or no transport, are able to attend lifesaving cancer treatment. Over 1000 volunteers provide the service free of charge and cover around 1 million kilometres each year. Their work was honoured in November 2017 by the Minister of Health.

### Volunteering strategic plan developed

This year we developed a new volunteering strategic plan to ensure that:

- people choose to volunteer with us because it's a rewarding experience
- all volunteering activities make a difference and are beneficial for the organisation and therefore our communities.

20 Cancer Society Annual Report 2018 Cancer Society Annual Report 2018 21

### Summary Statement of Comprehensive Revenue and Expense

National Office operational performance	2018	2017
Revenue  Divisional levies - supporting operations Royalties income Sales of resources and product Other revenue  Total revenue from operations  Expenditure Personnel costs Cost of resources and products sold Operating expenses  Total expenditure for operations	\$ 1,531,974 714,321 131,463 93,588 2,471,345  1,367,236 109,973 863,405 2,340,614	\$ 1,269,515 632,200 104,052 153,227 2,158,995  1,694,978 147,335 1,059,984 2,902,297
Net operating surplus / (deficit)	130,731	(743,302)
Scientific grants and scholarships programme		
Revenue Divisional levies - supporting the research programme Investment income and bequests for research  Total revenue  Expenditure Research grants Support for the International Cancer Benchmarking Programme	\$ 862,065 155,723 <b>1,017,788</b> 1,868,319 58,998	\$ 1,705,284 158,832 <b>1,864,116</b> 1,315,843 57,080
Other research programme support  Total expenditure	184,757 <b>2,112,074</b>	107,587 <b>1,480,510</b>
Net operating (deficit) / surplus	(1,094,286)	383,606
Income received and distributed to Divisions		
Revenue Daffodil Day income Bequests, donations and sponsorship Total revenue Expenditure Daffodil Day expenditure Other costs Total expenditure Net income distributed to Divisions Net result	\$ 1,124,210 188,117 1,312,327 452,655 5,906 458,561 853,766	\$ 1,124,699 254,663 1,379,362  445,586 45,732 491,318 888,044
Summary of results		
Net operating surplus / (deficit) Net operating (deficit) / surplus from grant programme Net result from income received and distributed to Divisions	\$ 130,731 (1,094,286)	\$ (743,302) 383,606

(963,555)

Net result

### Summary Statement of Changes in Net Assets for the year ended 31 March 2018

Capital Reserves	2018	2017	
Opening capital reserve  Comprehensive revenue and expenses  Transfer out to research capital reserve  Closing capital reserve	\$ 509,611 (963,555) 1,094,286 <b>640,342</b>	\$ 1,252,913 (359,696) (383,606) <b>509,611</b>	
- ,	•	,	
Research Capital Reserve Opening research capital reserve Transfers in from capital reserve Restatement of prior year	3,532,233 (1,094,286)	3,148,628 383,606 (1)	
Closing research capital reserve	2,437,947	3,532,233	
Total equity	3,078,289	4,041,844	
Summary Statement of Financial Position as at 31 March 2018			
Assets Current assets Non-current assets Total assets	\$ 859,586 3,830,517 <b>4,690,103</b>	\$ 1,363,543 3,773,277 <b>5,136,820</b>	
Liabilities  Current liabilities  Non-current liabilities  Equity  Total liabilities & equity	351,633 1,260,181 3,078,289 <b>4,690,103</b>	499,651 595,325 4,041,844 <b>5,136,820</b>	
Summary Statement of Cash Flows for the year en	nded 31 March 2018		
Net cash flow from operating activities Net cash flow from investing activities Net cash flow	\$ (468,188) 18,308 ( <b>449,880</b> )	\$ (815,511) 539,749 <b>(275,762)</b>	

22 | Cancer Society Annual Report 2018 | 23

(359,696)

# Notes to the summary report

The summary financial statements comprising of Cancer Society of New Zealand Incorporated and its controlled entity Daffodil Enterprises Limited, together (the 'Group') are presented for 2018.

The information was extracted from the full financial statements as audited by BDO Wellington. These were approved by the Cancer Society of New Zealand Board on 3 September 2018. They cannot be expected to provide as complete an understanding as provided by the full financial report. The full accounts are available on application to the Cancer Society of New Zealand Incorporated at PO Box 651, Wellington.

The presentation currency is New Zealand dollars. All amounts are stated in dollars.

The financial statements have been presented in a new format this year to help readers better understand the different activities managed by the National office.

# Statement of compliance

The full 'Group' financial statements have been prepared in accordance with generally accepted accounting practice in New Zealand ('NZ GAAP'). They comply with Public Benefit Entity International Public Sector Accounting Standards ('PBE IPSAS') and other applicable financial reporting standards as appropriate that have been authorised for use by the External Reporting Board for not-for-profit entities. For the purposes of complying with NZ GAAP, the group is a public benefit not-for-profit entity and is eligible to apply to Tier 2 not-for-profit PBE IPSAS on the basis that it does not have public accountability and has between \$2m and \$30m operating expenditure.

The Cancer Society of New Zealand Board has elected to report in accordance with Tier 2 not-for-profit PBE Accounting Standards and in doing so has taken advantage of all applicable Reduced Disclosure Regime ('RDR') disclosure concessions.

The summary financial statements have been prepared in accordance with FRS-43: Summary Financial Statements.

# **Auditors report**



**BDO** Wellington Audit Limited

## REPORT OF THE INDEPENDENT AUDITOR ON THE SUMMARY FINANCIAL STATEMENTS To the Members of Cancer Society of New Zealand Incorporated

### Opinion

The summary financial statements, which comprise the summary statement of financial position as at 31 March 2018, the summary statement of comprehensive revenue and expense, summary statement of changes in net assets and summary statement of cash flows for the year then ended, and related notes, are derived from the audited consolidated financial statements of Cancer Society of New Zealand Incorporated for the year ended 31 March 2018.

In our opinion, the accompanying summary financial statements are consistent, in all material respects, with the audited consolidated financial statements, in accordance with FRS-43: *Summary Financial Statements* issued by the New Zealand Accounting Standards Board.

### **Summary Financial Statements**

The summary financial statements do not contain all the disclosures required by Public Benefit Entity International Public Sector Accounting Standards ("PBE IPSAS") Tier 2 reduced disclosure regime. Reading the summary financial statements and the auditor's report thereon, therefore, is not a substitute for reading the audited financial statements and the auditor's report thereon. The summary financial statements and the audited financial statements do not reflect the effects of events that occurred subsequent to the date of our report on the audited financial statements.

### The Audited Financial Statements and Our Report Thereon

We expressed an unmodified audit opinion on the audited consolidated financial statements in our report dated 3 September 2018.

### Boards' Responsibility for the Summary Financial Statements

BDO Wellington Audit Cinifed

The Board is responsible on behalf of the entity for the preparation of the summary financial statements in accordance with FRS-43: Summary Financial Statements.

### Auditor's Responsibility

Our responsibility is to express an opinion on whether the summary financial statements are consistent, in all material respects, with the audited financial statements based on our procedures, which were conducted in accordance with International Standard on Auditing (New Zealand) (ISA (NZ)) 810 (Revised), Engagements to Report on Summary Financial Statements.

Other than in our capacity as auditor we have no relationship with, or interests in, the entity or any of its subsidiaries.

BDO Wellington Audit Limited

Wellington New Zealand 3 September 2018

# **Daffodil Enterprises Limited**



Daffodil Enterprises Ltd has been delivering award winning, high quality sunscreens and sun-related products to the New Zealand market since 1997.

For the last 21 years,
Daffodil Enterprises Ltd
has dedicated its work
to managing the sale
and distribution of high
quality sunscreens, hats,
sunglasses, prescription
lenses and UPF50+ rated
clothing, both in New
Zealand and off-shore.
Daffodil Enterprises Ltd
voluntarily adhere to AS/
NZS Standards and this is
reflected in the quality of
their products.

CSNZ is a member of Standards New Zealand and Daffodil Enterprises Ltd is their representative, active in a number of committees.

Daffodil Enterprises
Ltd takes pride in their
contribution to raising
funds through the sales
of products to support
the core activities of the
Cancer Society of New
Zealand.



Daffodil Enterprises Limited is a wholly owned company of the Cancer Society of New Zealand Incorporated (CSNZ).



Annual Report of the Cancer Society of New Zealand Inc, Te Kāhui Matepukupuku o Aotearoa Level 6 Ranchhod Tower 39 The Terrace Wellington

Phone (04) 494 7270

PO Box 651, Wellington 6140

ISSN 2463-3216

Charity no: CC30617 Incorporated Societies no: 215593 GST no: 19-351-769

www.cancernz.org.nz

CANCER INFORMATION HELPLINE 0800 CANCER (226 237)

